Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IntercureINCR 69 EV-to-EBITDA is -48.32 as of Sep. 21, 2026. GuruFocus rates INCR with a GF Score™ of 69/100 and a GF Value™ of $5.74 (Fairly Valued). The stock has 5 warning signs investors should review. Among 745 Drug Manufacturers companies, Intercure ranks worse than 134228.05% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Intercure's enterprise value is $125.42 Mil.
Intercure's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.60 Mil. Therefore, Intercure's EV-to-EBITDA for today is -48.32.
The historical rank and industry rank for Intercure's EV-to-EBITDA or its related term are showing as below:
INCR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -114.97 Med: -13.17 Max: 31.87
Current: -48.31
During the past 13 years, the highest EV-to-EBITDA of Intercure was 31.87. The lowest was -114.97. And the median was -13.17.
INCR's EV-to-EBITDA is ranked worse than 100% of 745
companies
in the Drug Manufacturers industry
Industry Median: 12.56
vs INCR: -48.31
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Intercure's share price for today is $5.31.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Intercure's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-1.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Intercure's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Intercure's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intercure EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Intercure's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Intercure's EV-to-EBITDA falls into.
Intercure's current Enterprise Value is $125.42 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Intercure's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intercure (INCR) has a EV-to-EBITDA of -48.32 as of Sep. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Intercure. According to the industry distribution chart, Intercure ranks #999999 out of 745 companies in the Drug Manufacturers industry.
Is Intercure's EV-to-EBITDA too high?
Intercure's current EV-to-EBITDA is -48.32. Based on the distribution chart, Intercure ranks #999999 out of 745 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Intercure has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Intercure's EV-to-EBITDA compare to CTOR and ZYBT?
According to the Drug Manufacturers industry distribution chart, Intercure ranks #999999 out of 745 companies for EV-to-EBITDA. This places Intercure in the lower half of its industry. The industry median EV-to-EBITDA is 12.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.56, based on 745 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Intercure. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intercure's current EV-to-EBITDA is -48.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intercure stock overvalued right now?
Based on GuruFocus' analysis, Intercure (INCR) is currently considered Fairly Valued. The stock's GF Value™ is $5.74, compared to a current price of $5.31 — trading 7.5% below its estimated fair value. The current EV-to-EBITDA is -48.32. Intercure's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Intercure (INCR), the current EV-to-EBITDA is -48.32 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intercure (INCR) Overvalued in 2026?
Based on GuruFocus' analysis, Intercure stock appears to be undervalued.
The current stock price of $5.31 is trading 7.5% below its estimated GF Value™ of $5.74.
GuruFocus considers Intercure to be Fairly Valued.
Key valuation signals for INCR:
EV-to-EBITDA: -48.32
GF Value™: $5.74 vs. price of $5.31 (7.5% below fair value)
No single metric tells the full story. See the INCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
69GF Score
Get the complete analysis for INCR
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INCR has been successfully added to your 
